Novavax's president and CEO reviewed the company's achievements in 2025 and presented a growth strategy for 2026 and beyond at a recent conference.[1][2] Matrix-M technology is central to Novavax's strategy, serving as an adjuvant that enhances both antibody and cell-mediated immune responses and has demonstrated a favorable safety profile in clinical trials.[1][3] Matrix-M is used in the approved COVID-19 vaccine Novavax and in the R21/Matrix-M malaria vaccine.[1][4] The deal with Sanofi includes sales of the COVID-19 vaccine starting in 2025, with an initial payment of €500 million, an investment of €70 million and potential milestones of up to $200 million for the first four Matrix-M products, plus royalties.[2][3][5] Sanofi has extended the license to Matrix-M for its pandemic influenza vaccine candidate into Phase 2.[3] Novavax is developing an early-stage pipeline including C. difficile, zoster, VRS and pandemic influenza vaccines, with positive Phase 1/2 data for a combination influenza and COVID-19 vaccine.[2] The firm plans more partnerships for Matrix-M and aims for diversified income.[2][3]